A molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the Clinical Molecular Diagnostic, Industrial and Biothreat markets.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
CPHD reporting 3rd quarter earning today (11-1-07). Total revenues up 53% compared to 3rd quarter 2006 due mainly to their new "GeneXpert(R) System" which provides rapid detection of Methicillin- resistant Staphylococcus aureus (MRSA). MRSA has had a lot of press recently and this rapid testing is a need in hospitals and medical facilities to detect drug-resistant organisms for quick treatment. I listened to their webcast of their earnings this pm and they are really increasing the number of sales of this system. This one will go higher and I would not be surprised to hear news that this company would be an M&A target. This one will go higher.